Table 3.
Evaluation of niclosamide-ivermectin combination treatments against SARS-CoV-2 in Calu-3 cells
| Drug treatment | IC50 (μM) |
Fold reduction of IC50 (single/combined) |
|---|---|---|
| Niclosamide-ivermectin | ||
| Niclosamide | 0.20 | |
| Niclosamide + ivermectin 0.4 μM | ND | ND |
| Niclosamide + ivermectin 0.2 μM | ND | ND |
| Niclosamide + ivermectin 0.1 μM | 0.084 | 2.38 |
| Niclosamide + ivermectin 0.05 μM | 0.086 | 2.33 |
| Ivermectin | 0.20 | |
| Ivermectin + niclosamide 0.4 μM | ND | ND |
| Ivermectin + niclosamide 0.2 μM | ND | ND |
| Ivermectin + niclosamide 0.1 μM | 0.055 | 3.64 |
| Ivermectin + niclosamide 0.05 μM | 0.083 | 2.41 |
ND not determined, cannot calculate IC50 with the least curve fit of the data sets